Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.
As Curis clinically backs a novel oncology mechanism, several companies might review their own similarly acting projects.
This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.
A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?
A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.